Project Grant R01AI195933
- Federal Grant Award Summary The University of Notre Dame received a $659,122 Project Grant awarded on August 12, 2025, from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research will be conducted through July 31, 2030, and focuses on understanding pH-dependent switching mechanisms of the ESX-1 secretion system in mycobacterial pathogenesis. The project examines how pathogenic mycobacteria,...
- Federal Grant Award Summary The University of Notre Dame DU Lac received a $769,354 Project Grant award from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective May 22, 2026, through April 30, 2031. This research initiative addresses the urgent public health threat of Clostridioides difficile infections by investigating spore germination mechanisms and developing novel therapeutic interventions. The project...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Notre Dame Du Lac $705,896 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 12, 2025, to support a Project Grant investigating emerging artemisinin partner drug resistance in Eastern Africa. The five-year initiative, scheduled for completion by July 31, 2030, addresses the critical public health challenge of lumefantrine resistance in...
- Federal Grant Award Summary The University of Notre Dame received a $414,725 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded September 1, 2025, with completion targeted for July 31, 2030. The grant funds the Mobashery Laboratory's research on targeting gram-negative bacteria, specifically Pseudomonas aeruginosa, through investigation of bacterial cell wall biosynthesis and recycling...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $234,750 to the University of Notre Dame DU Lac under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 15, 2025, for an exploratory research project extending through June 30, 2027. This R21 grant funds scientific investigation into polymicrobial interactions during catheter-associated urinary tract infections (CAUTIs), specifically examining cross-kingdom...
- Federal Grant Award Summary The University of Notre Dame DU Lac received a $459,439 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 7, 2025, with completion scheduled for June 30, 2027. The grant supports research addressing acute cellular rejection (ACR) in organ transplantation through investigation of CD8+ T cell alloreactivity and its relationship to viral...
- Federal Grant Award Summary The University of Notre Dame received a $464,176 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded April 3, 2026, with a completion date of March 31, 2028. This research initiative focuses on developing and evaluating species-specific yeast ribonucleic acid interference (RNAi) pesticides for controlling sand fly vectors of leishmaniasis. The project...
- Federal Project Grant Award Summary The University of Notre Dame received a $387,857 Project Grant awarded September 1, 2025, through the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) to develop a molecular recognition guidebook for targeting protein loops with covalent ligands. The five-year research initiative (concluding August 31, 2030) will establish systematic guiding principles for understanding how small molecule...
- Federal Project Grant Award Summary The University of Notre Dame DU Lac received a $622,340 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective June 1, 2025, through May 31, 2027. The award supports research into multispecific bridge nanoparticles designed to engage T cells and off-the-shelf chimeric antigen receptor (CAR)-T cells against antigen-positive endothelial cell (EC) tumors to enhance antitumor immune...
- Federal Grant Award Summary The University of Notre Dame Du Lac received a $430,375 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), effective August 1, 2025 through July 31, 2027. The award supports development of supramolecular engineered glucagon-like peptide 1 receptor agonist (GLP-1 RA) depots designed to provide multi-month...
The University of Notre Dame DU Lac received a $748,964 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective May 22, 2026, with completion targeted for April 30, 2031. The grant supports research to develop and optimize boron-based small molecule inhibitors that target the BlaR protein in methicillin-resistant Staphylococcus aureus (MRSA) and related antibiotic-resistant variants. The research aims to produce novel adjuvant compounds that restore bacterial sensitivity to beta-lactam antibiotics by blocking the antibiotic resistance signal transduction mechanism, with lead compound 15 demonstrating 16- to 4,096-fold potentiation of existing antibiotics in preclinical models. The deliverables include optimization of boron-based adjuvants to achieve drug-like properties suitable for both mechanistic research tools and potential therapeutic development. Research activities are being conducted at the University of Notre Dame's Research Division in Notre Dame, Indiana, and are designed to advance understanding of MRSA resistance mechanisms while generating intellectual property and therapeutic candidates intended to address a significant public health threat, with MRSA causing over 323,000 hospitalizations and 10,000 deaths annually in the United States.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $749.0k | 5/26/26 |